PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries

Reinach, 28 September 2023 — Evolva (SIX: EVE), a pioneer in the field of natural molecules and industrial biotech, and LEHVOSS UK Ltd. (“LEHVOSS”), a leading European distributor with technical sales and marketing expertise supplying branded and high quality ingredients to a variety of industries in nutrition, personal care and other market segments, have signed an agreement for the distribution of Evolva’s Veri-te^TM Resveratrol in over a dozen European countries for use in dietary supplements through LEHVOSS subsidiaries and expert teams across Europe. Sales from the agreement are expected to amount to around CHF 1.5 million by the end of 2025.

Over a dozen European countries are covered under the agreement. It is anticipated that the agreement will generate approximately CHF 1.5 million in sales by the conclusion of 2025.

The agreement is further testimony to Evolva’s market expansion activities. Following market launch and successful entry into five South-East Asian countries as well as Brazil with Veri-te^TM Resveratrol for use in foods and dietary supplements over the recent past, the agreement with LEHVOSS now also paves the way to strengthen distribution in important European countries. Veri-te^TM Resveratrol is the main pillar of Evolva’s Health Ingredients (HI) business and was a key driver for the 14% revenue growth in HI recorded in the first half of 2023.

Anne De Vos, Chief Commercial Officer of Evolva, comments: ”We are very excited to strengthen the presence of our Veri-te^TM Resveratrol across a wider range of European countries. Veri-te^TM Resveratrol is a responsible multi-functional ingredient with proven health benefits supported by a number of clinical studies. We consider LEHVOSS to be an ideal partner for the distribution of Veri-te^TM Resveratrol due to its exceptional market capabilities.”

Teresita Rudà, Head of Brands and Marketing for LEHVOSS Nutrition adds: “We are thrilled to add this high quality, researched and sustainable brand to our portfolio. We are convinced that Veri-te™ Resveratrol will add strength to our specially selected offer of ingredients across Europe and we look forward to a successful partnership with Evolva.”
 

Contact
Doris Rudischhauser
Head of Investor Relations and Corporate Communications
+41 79 410 81 88
dorisr@evolva.com
 

About Veri-teTM Resveratrol
Resveratrol is a polyphenolic compound that occurs naturally in plants such as grapes, peanuts, cranberries and other berries, albeit at low concentrations. Evolva’s Veri-te^TM Resveratrol is a nature-based high-purity ingredient, made via fermentation, which ensures a stable, traceable and reliable supply. The ingredient is offered in different formats such as a cold-water dispersible or an oil and water-soluble resveratrol and is sold for use in dietary supplements, functional beverages, cosmetics, pharma applications and animal health market
 

About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees are dedicated to make the best products that can contribute to health, wellness and sustainability. Find out more at evolva.com and connect with us on LinkedIn.

About LEHVOSS Nutrition
LEHVOSS Nutrition is a business division of the Hamburg based LEHVOSS Group, dedicated to the marketing and distribution of nutraceutical ingredients and minerals for Food Supplements, Functional Foods and Pet food applications, throughout Europe. Their ingredients’ portfolio covers Women’s Health, Healthy Aging, Weight Management, Beauty Within, Immune Support, Joint Health, Cardiovascular, Cognitive, Gut Health, Sport Nutrition and more.

To learn more about LEHVOSS Nutrition visit www.lehvoss-nutrition.com or follow us on LinkedIn.
 

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.             
This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.